# APEX-Breast01: HCP commentary report

> 39 verified statements (7 from clinicians verified by NPI or staff page) from 12 commentary sources · 6 findings · updated Oct 29, 2026

## Report

- Trial: A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- NCT ID: NCT06561607
- Registry: https://clinicaltrials.gov/study/NCT06561607
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Phase: Phase 3
- Status: Active, not recruiting
- Indications: Breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 6c50ca10cfb120f45b0a1b7a73964fee9a145c954f9e0f727148e27772a78521

## Counts

- HCP commentary sources screened: 18
- Sources cited by verified statements: 13
- Verified statements: 39
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 7
- Findings: 6
- People found in screened sources: 11
- Voices cited: 11
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

APEX-Breast01 asks whether TQB2102 delays cancer progression compared with chemotherapy in HR-positive, HER2-low advanced breast cancer without prior chemotherapy for advanced disease. An X poster leaves TQB2102’s place among available ADCs unsettled. That poster welcomes efficacy, while treatment toxicity draws scrutiny in another X post. In the YouTube discussion, whether TQB2102 extends survival and adds clinical value over existing ADCs remains an open question.

## Open Medical Affairs question

What added efficacy–safety value over T-DXd or another locally available ADC would justify TQB2102’s place in the treatment pathway?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The unresolved comparator question is T-DXd, not chemotherapy alone
- F2. Manageability language coexists with higher severe toxicity and unresolved long-term safety
- F3. Strong efficacy enthusiasm does not establish an overall-survival benefit
- F4. The biparatopic design has a rationale, but its added clinical contribution remains unproven
- F5. Matching PFS medians and nearby hazard ratios do not support an ADC ranking
- F6. Practical placement remains conditional on available alternatives, benefit–risk and regulatory status

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 8 | 11 | 6 | 6 | recorded | 2 |
| F2 | 8 | 8 | 6 | 5 | recorded | 3 |
| F3 | 17 | 15 | 10 | 9 | recorded | 3 |
| F4 | 10 | 9 | 5 | 5 | recorded | 3 |
| F5 | 5 | 5 | 1 | 0 | none recorded | 2 |
| F6 | 5 | 6 | 5 | 4 | recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 3 | 1 | 0 | 4 | 0 | 10 | 2 | 5 posts and articles, 1 podcast or video | yes |
| F2 | 3 | 1 | 0 | 1 | 3 | 10 | 2 | 5 posts and articles, 1 podcast or video | yes |
| F3 | 7 | 3 | 0 | 1 | 6 | 18 | 4 | 9 posts and articles, 1 podcast or video | yes |
| F4 | 3 | 2 | 0 | 1 | 4 | 11 | 1 | 4 posts and articles, 1 podcast or video | yes |
| F5 | 2 | 1 | 0 | 2 | 0 | 7 | 5 | 1 podcast or video | yes |
| F6 | 3 | 2 | 0 | 0 | 0 | 5 | 1 | 4 posts and articles, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC): F1 (2 shared claims), F3 (5 shared claims)
- Secondary endpoints: F2 (4 shared claims), F3 (8 shared claims)
- Population and setting: F1 (2 shared claims), F2 (1 shared claims), F3 (6 shared claims), F4 (1 shared claims), F5 (2 shared claims)
- The comparison: F1 (5 shared claims), F2 (1 shared claims), F3 (5 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (8 shared claims), F3 (6 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (2 shared claims), F3 (4 shared claims), F4 (2 shared claims), F5 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. The unresolved comparator question is T-DXd, not chemotherapy alone

X posts raise questions about head-to-head ADC studies and comparisons of efficacy and safety between TQB2102 and T-DXd.

The posters’ clinical roles are not confirmed in the sources reviewed for this edition.

Not every part of these threads was examined, so additional views or qualifications may be missing.

Source: X thread, 2026-10-23.

### F5. Matching PFS medians and nearby hazard ratios do not support an ADC ranking

A YouTube discussion asks how progression-free survival results can be compared between TQB2102 and SHR-A1811.

The speaker is not identified, and their clinical role is not stated in the sources reviewed for this edition.

Not every part of the video was examined, so additional views or qualifications may be missing.

Source: YouTube video, 2026-10-26.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 39 | Paid |
| Trial aspects mapped | 10 | Free |
| Sources with links | 13 | Counts free |
| Speaker attribution for cited voices | 11 | Paid |

## Trial aspects

10 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC) | discussed | 6 | 5 |
| Secondary endpoints | discussed | 8 | 7 |
| Population and setting | discussed | 8 | 5 |
| The comparison | discussed | 7 | 5 |
| Safety and tolerability | discussed | 9 | 6 |
| Design and conduct | discussed | 9 | 4 |
| APEX-Breast01: biparatopic differentiation and perceived ADC similarity | discussed | 8 | 5 |
| APEX-Breast01 and HORIZON-Breast06: limits of numerical ranking | discussed | 5 | 1 |
| TQB2102 placement relative to T-DXd and internationally available alternatives | discussed | 8 | 7 |
| TQB2102 application acceptance versus marketing approval | discussed | 1 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 16 | 11 |
| YouTube | 2 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2026-10-23 to 2026-10-26
- Cited window: 2026-10-23 to 2026-10-26
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- Also known as: APEX-B01
- Registry: NCT06561607 (https://clinicaltrials.gov/study/NCT06561607)
- Study IDs: TQB2102-III-01
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 542 (estimated)
- Start: 2024-10-11 (actual)
- Primary completion: 2027-01 (estimated)
- Primary endpoint: Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC) (Up to 25 months)
- Intervention: TQB2102 for Injection (drug)
- Intervention: Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on chemotherapy-naive patient selection, progression-free survival and interstitial lung disease with the trial intervention versus chemotherapy.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 18 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are a limited collection of posts and a video, not a representative sample of HCP opinion. Reposts and repeated quotations should not be counted as independent endorsements.
- Parts of several sources were not fully assessed. Discussion using alternative wording, transcription variants or no trial name may be missing, so the report cannot establish that all relevant views or qualifications have been captured.
- The video’s explanation of activity below the conventional HER2-positive threshold concerns possible therapeutic effects of certain ADCs, not guaranteed activity. Its diagnostic-selection rationale should not be read as an additional APEX-Breast01 efficacy result.
- No full protocol or exact-trial results publication was available. The registry material describes planned methods and has no posted results; efficacy and safety figures in this report remain attributed accounts from commentary.
- No exact regulatory label matching the registry’s named interventions was available. The reported Chinese application acceptance does not independently establish marketing approval, access or reimbursement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The registry’s planned enrollment of 542 and commentary reports of 543 participants are not reconciled here. Differences in reported response populations and safety summaries should likewise not be combined into a single independently verified dataset.
- Cross-trial comparisons cannot establish that a control arm was weak, that similar medians imply equivalent efficacy, or that one ADC is safer. The report preserves those interpretations and cautions as expressed rather than adjudicating them.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (39 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/apex-breast01-nct06561607
- Agents: POST https://www.erudio.com/api/orders with {"report": "apex-breast01-nct06561607", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=apex-breast01-06561607

## Cite

Erudio Health. APEX-Breast01 (NCT06561607): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/apex-breast01-nct06561607

## Machine access

- JSON: https://www.erudio.com/reports/apex-breast01-nct06561607.json
- Markdown: https://www.erudio.com/reports/apex-breast01-nct06561607.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "apex-breast01-06561607"}`